+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Variability in response to NSAIDs: what progress?

Variability in response to NSAIDs: what progress?

Agents and Actions. Supplements 44: 3-6

Little further work has established the nature and importance of variability in response to NSAIDs despite the phenomenon being identified by Huskisson in 1976. The following questions remain unanswered: the proportion of individuals who display marked variability in responses to different NSAIDs; reproducibility of individual responses over repeated exposures; the influence of various musculoskeletal disorders on the level of variability in response; and the importance of pharmacokinetic or pharmacodynamic mechanisms. Data continue to accumulate that there is a weak relationship between concentration of NSAIDs in plasma and degree of efficacy in RA and now OA and acute pain states, as well as with the incidence of toxicity, notably GI bleeding. The efficacy relationship may resemble a rectangular hyperbola with a steep slope upwards. None of the proposed mechanisms of action of NSAIDs additional to the universal ability to inhibit prostaglandin synthesis, which have been suggested as possible causes of response differences between drugs, has been linked rigourously to responses in individual patients. Systematic work linking clinical responses to pharmacokinetic parameters and pharmacodynamic mechanisms is required to understand variability of responses to NSAID therapy.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 034181611

Download citation: RISBibTeXText

PMID: 8372731

Related references

Variability in Response to Nsaids. Drugs 36(6): 643-651, 1988

Variability in response to NSAIDs. Fact or fiction?. Drugs 36(6): 643-651, 1988

Cytochrome P450 Gene Polymorphisms and Variability in Response to Nsaids. Clinical Research and Regulatory Affairs 22(2): 57-81, 2005

Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. Cancer Prevention Research 7(2): 246-254, 2014

SAT0360Combined Therapy with Rituximab and NSAIDS in Treatment of Active Ankylosing Spondylitis: Better than NSAIDS Alone, Worse than Combination of Tnf-Inhibitors and Nsaids. Annals of the Rheumatic Diseases 73(Suppl 2): 724.1-724, 2014

Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs?. Gastroenterology 109(2): 614-616, 1995

NSAIDs and the gastrointestinal tract: an update on recent progress. Journal of the American Osteopathic Association 99(8 Suppl.): S10-S13, 2000

Encapsulation of NSAIDs for inflammation management: Overview, progress, challenges and prospects. International Journal of Pharmaceutics 515(1-2): 757-773, 2016

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development. Pharmaceuticals 3(5): 1530-1549, 2010

FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. Frontiers in Pharmacology 7: 353, 2016

Investigation of the HPLC response of NSAIDs by fractional experimental design and multivariate regression analysis. Response optimization and new retention parameters. Journal of Pharmaceutical and Biomedical Analysis 51(1): 46-55, 2010

Variability in histamine receptor genes HRH1, HRH2 and HRH4 in patients with hypersensitivity to NSAIDs. Pharmacogenomics 14(15): 1871-1878, 2014

NSAIDs reduce mitochondrial ATP levels Further evidence that NSAIDs uncouple oxidative phosphorylation. British Journal of Rheumatology 36(SUPPL 1): 193, 1997

Topical NSAIDs are better than placebo. Safety, efficacy, and therapeutic role of nsaids must be clarified. BMJ 317(7153): 280-1, 281, 1998

Comparison of NSAIDs and NO-NSAIDs on PGE2 and GMCSF production by human synoviocytes. British Journal of Pharmacology 128(PROC SUPPL ): 98P, 1999